Efficacy	O
of	O
MMF	O
in	O
current	O
immunosuppressive	O
regimens	O
after	O
kidney	B-Organ
transplantation	O

Current	O
established	O
immunosuppressive	O
strategies	O
in	O
kidney	B-Organ
transplantation	O
often	O
include	O
an	O
induction	O
agent	O
(	O
monoclonal	O
or	O
polyclonal	O
anti	O
-	O
T	B-Cell
-	I-Cell
cell	I-Cell
antibodies	O
)	O
based	O
on	O
the	O
immunologic	O
risk	O
of	O
the	O
recipient	O
,	O
followed	O
by	O
a	O
maintenance	O
regimen	O
combining	O
a	O
CNI	O
and	O
an	O
anti	O
-	O
proliferative	O
agent	O
,	O
with	O
or	O
without	O
corticosteroids	O
.	O
2	O
-	O
4	O
As	O
MMF	O
was	O
the	O
first	O
MPA	O
formulation	O
approved	O
in	O
clinical	O
kidney	B-Organ
transplantation	O
,	O
more	O
extensive	O
clinical	O
data	O
are	O
available	O
with	O
this	O
drug	O
in	O
comparison	O
to	O
EC	O
-	O
MPS	O
.	O

